If you’ve been hesitant about investing on Wall Street because you think it’s only for the wealthy, here’s some encouraging news. Today, discount brokerages have significantly reduced trading fees, making it possible for everyone – even those who invest small amounts – to potentially earn returns comparable to wealthier investors who make larger trades.
Currently, individuals with a spare $100 can easily invest in shares of Healthpeak Properties (DOC) and Pfizer (PFE). Both of these stocks currently provide dividend yields that exceed 6% at their recent prices. Moreover, there are compelling reasons to anticipate increases in the dividends from these stocks in the short term. Keep reading to discover why they seem to be excellent choices for everyday investors who aim to expand their passive income streams.
1. Healthpeak Properties
Last year, this healthcare real estate investment trust (REIT) grew through a merger between Physicians Realty Trust and Healthpeak. Prior to the merger, Healthpeak primarily specialized in leasing out laboratories to pharmaceutical companies of various sizes.
By incorporating Physicians Realty Trust’s collection of medical office buildings, the REIT gained a desirable level of diversification that appeals to investors. As of March’s end, health systems and physician groups accounted for approximately 55% of the annualized rental base, while drug manufacturers of assorted sizes were responsible for about 34%. The remaining portion of the portfolio included continuing care retirement communities, as well as other facilities.
Among its tenants, HCA Healthcare, a publicly-traded hospital management company, accounts for the largest portion (10.1%) of Healthpeak’s annualized rent. The second largest tenant, CommonSpirit Health, contributes approximately 2.9%.
In simple terms, investors may anticipate higher dividends from Healthpeak Properties’ stock soon. The management forecasts their Funds From Operations (FFO) to be within the range of $1.81 to $1.87 per share this year. This projected FFO exceeds the current required amount for maintaining the existing annualized dividend of $1.22 per share, suggesting a potential increase in dividends.
Most of Healthpeak’s properties are leased out under net leases, meaning the tenants typically cover almost all expenses related to maintaining these buildings. Since many long-term leases include annual rent escalators, investors can anticipate that this Real Estate Investment Trust (REIT) will likely increase its dividend payout consistently over a longer period.
2. Pfizer
Over the past four years, the stocks of the biggest pharmaceutical company in America have dropped approximately 60% from their highest point reached in 2021. While these declines might not be ideal for long-term capital growth, income-focused investors have been thriving.
Year after year since 2009, Pfizer has consistently increased its dividend payouts. Currently, at its current low price, it provides a striking 6.9% dividend return.
Besides the sudden drop in revenue due to COVID-19, Pfizer’s shares have also fallen significantly as investors express concerns over impending patent expirations affecting their best-selling drugs.
It’s understandable for investors to express worry about Pfizer’s future income streams. This year, the CEO, Albert Bourla, forecasted that losses of market exclusivity could potentially decrease revenue by around $17 billion to $18 billion from 2026 to 2028.
Over the past year ending in March, the company saw a significant increase in total sales to $62.5 billion. However, compensating for any gaps in income due to exclusivity losses won’t be a straightforward task. Fortunately, the company wisely channeled a large portion of its COVID-19 financial boost into a fruitful research and development pipeline.
In the year 2023, the Food and Drug Administration endorsed nine novel medications from Pfizer. The following year, 2024, saw the company receiving more than a dozen FDA approvals, including both new and existing therapies. By the year 2030, management anticipates that products Pfizer has recently acquired will generate an annual revenue of $20 billion. This substantial earnings potential will enable the company to continue its growth trajectory, even in light of anticipated losses due to patent expirations.
In 2023, Pfizer purchased Seagen for $43 billion, granting them control over numerous groundbreaking cancer treatments. Previously, the manufacturers of these therapies were outsourced, but Pfizer’s intention to bring manufacturing operations in-house could lead to a quicker increase in profits compared to sales growth in the upcoming years.
As an eager investor, I don’t foresee swift escalations in dividend payouts from this stock in the upcoming years. However, a consistent progression towards growth seems promising. Adding a few shares to a well-balanced portfolio today appears to be a shrewd decision for those investors seeking substantial dividends that could potentially expand further.
Read More
- Gold Rate Forecast
- KPop Demon Hunters: Is Your Idol by Saja Boys Inspired by Real K-Pop Bands? Here’s What We Know
- Justin Bieber Teases New Album ‘SWAG’ with Tracklist Reveal
- 15 Best Sherlock Holmes Actors, Ranked from Worst to Best
- Ultraman Live Stage Show: Kaiju Battles and LED Effects Coming to America This Fall
- Superman’s Record-Breaking $21M+ Thursday Box Office: Highest of 2025
- 📢 BrownDust2 X BiliBili World 2025 Special Coupon!
- Tokyo Game Show 2025 exhibitors announced
- Superman’s Rotten Tomatoes Score Blasts Past Expectations—Shocks Even the Harshest Critics
- Dakota Johnson-Anne Hathaway’s Verity Release Date Out: Here’s When Colleen Hoover’s Movie Adaptation Will Hit the Screens
2025-07-19 14:11